TY - JOUR
T1 - A computer-based approach to the rational discovery of new trichomonacidal drugs by atom-type linear indices
AU - Marrero-Ponce, Yovani
AU - Machado-Tugores, Yanetsy
AU - Pereira, David Montero
AU - Escario, José Antonio
AU - Barrio, Alicia Gómez
AU - Nogal-Ruiz, Juan José
AU - Ochoa, Carmen
AU - Arán, Vicente J.
AU - Martínez-Fernández, Antonio R.
AU - García Sánchez, Rory N.
AU - Montero-Torres, Alina
AU - Torrens, Francisco
AU - Meneses-Marcel, Alfredo
PY - 2005/12
Y1 - 2005/12
N2 - Computational approaches are developed to design or rationally select, from structural databases, new lead trichomonacidal compounds. First, a data set of 111 compounds was split (design) into training and predicting series using hierarchical and partitional cluster analyses. Later, two discriminant functions were derived with the use of non-stochastic and stochastic atom-type linear indices. The obtained LDA (linear discrimination analysis)-based QSAR (quantitative structure-activity relationship) models, using non-stochastic and stochastic descriptors were able to classify correctly 95.56% (90.48%) and 91.11% (85.71%) of the compounds in training (test) sets, respectively. The result of predictions on the 10% full-out cross-validation test also evidenced the quality (robustness, stability and predictive power) of the obtained models. These models were orthogonalized using the Randić orthogonalization procedure. Afterwards, a simulation experiment of virtual screening was conducted to test the possibilities of the classification models developed here in detecting antitrichomonal chemicals of diverse chemical structures. In this sense, the 100.00% and 77.77% of the screened compounds were detected by the LDA-based QSAR models (Eq. 13 and Eq. 14, correspondingly) as trichomonacidal. Finally, new lead trichomonacidals were discovered by prediction of their antirichomonal activity with obtained models. The most of tested chemicals exhibit the predicted antitrichomonal effect in the performed ligand-based virtual screening, yielding an accuracy of the 90.48% (19/21). These results support a role for TOMOCOMD-CARDD descriptors in the biosilico discovery of new compounds.
AB - Computational approaches are developed to design or rationally select, from structural databases, new lead trichomonacidal compounds. First, a data set of 111 compounds was split (design) into training and predicting series using hierarchical and partitional cluster analyses. Later, two discriminant functions were derived with the use of non-stochastic and stochastic atom-type linear indices. The obtained LDA (linear discrimination analysis)-based QSAR (quantitative structure-activity relationship) models, using non-stochastic and stochastic descriptors were able to classify correctly 95.56% (90.48%) and 91.11% (85.71%) of the compounds in training (test) sets, respectively. The result of predictions on the 10% full-out cross-validation test also evidenced the quality (robustness, stability and predictive power) of the obtained models. These models were orthogonalized using the Randić orthogonalization procedure. Afterwards, a simulation experiment of virtual screening was conducted to test the possibilities of the classification models developed here in detecting antitrichomonal chemicals of diverse chemical structures. In this sense, the 100.00% and 77.77% of the screened compounds were detected by the LDA-based QSAR models (Eq. 13 and Eq. 14, correspondingly) as trichomonacidal. Finally, new lead trichomonacidals were discovered by prediction of their antirichomonal activity with obtained models. The most of tested chemicals exhibit the predicted antitrichomonal effect in the performed ligand-based virtual screening, yielding an accuracy of the 90.48% (19/21). These results support a role for TOMOCOMD-CARDD descriptors in the biosilico discovery of new compounds.
KW - Atom-Based Linear Index
KW - Cytocidal activity
KW - Heterocycles
KW - LDA-Based QSAR Model
KW - Lead Antitrichomonal Compound
KW - TOMOCOMD-CARDD Software
KW - Trichomonacidal Activity
KW - Virtual Screening
UR - http://www.scopus.com/inward/record.url?scp=31544434857&partnerID=8YFLogxK
U2 - 10.2174/157016305775202955
DO - 10.2174/157016305775202955
M3 - Artículo
C2 - 16475921
AN - SCOPUS:31544434857
SN - 1570-1638
VL - 2
SP - 245
EP - 265
JO - Current Drug Discovery Technologies
JF - Current Drug Discovery Technologies
IS - 4
ER -